Letter: Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently?

 jco letter

".....It is time that regulatory bodies accept that there are other meaningful ways to measure treatment benefit in the palliative setting rather that insisting on an improvement in OS as the only route to registration of new agents. The GCIG Symptom Benefit Study that is currently in progress....